The Legal Bridge A litigation-grade framework connecting Indian IP law, TRIPS exhaustion principles, Named Patient import regimes, and biologics early access governance into a coherent, defensible structure for cross- border Named Patient biologics supply and parallel movement.

TRIPS Foundation

Exhaustion as Sovereign Choice Article 6 Framework Under WTO TRIPS Agreement, members determine their own exhaustion regime. WTO dispute settlement cannot challenge this sovereign choice. Legal Consequence India can legally adopt international exhaustion, enabling movement of legitimately marketed products across borders without per se IP violation. First Structural Pillar Cross-border movement does not equal IP violation when properly structured within sovereign exhaustion frameworks.

Indian Law Layer

Lawful First Sale Logic Legal Foundation Combined reading of Patents Act Section 107A(b), judicial interpretation trends, and parallel import jurisprudence supports that lawful first sale reduces downstream patent control. Critical Reframing Do NOT argue: "Exports are unrestricted." Instead argue: "Exports of lawfully acquired genuine goods, where destination regulator authorises patient-specific import, do not defeat patent rights within India." Litigation Positioning This reframing transforms the legal narrative from defensive to structurally justified, making it significantly harder to attack in proceedings.

Two Legal Routes

Critical Distinction Route A: Section 107A(a) Purpose: regulatory submissions. Strong case law support. NOT ideal for Named Patient programmes. Route B: Your Strategy Exhaustion + humanitarian supply: lawful acquisition, no inducement, patient-initiated treatment, non-commercialised distribution. Your programme sits in Route B, not 107A. This is the first structural correction that most legal teams miss.

Destination Country Regulatory Authorisation Legal Classification Named Patient frameworks (e.g., Brazil under ANVISA) classify imports as patient-specific medical access, NOT commercial market entry. Breaking the IP Narrative When physician initiates, regulator approves, and patient is identified, export becomes medical fulfilment of a regulator-authorised treatment pathway. Shifting Legal Optics This transforms opposing counsel's "parallel export circumvents territorial exclusivity" argument into a significantly weaker position.

Governance Controls

Your Strongest Shield Named-Patient Only Physician initiation with identified patient ensures medical legitimacy and prevents commercial diversion. Oversight Committee Independent review body evaluates each request against strict humanitarian criteria. Hard Stop Triggers Automatic suspension mechanisms prevent uncontrolled distribution or commercialisation. Anti-Commercialisation Strict controls ensure activity remains within regulator-authorised pathways, not grey market. These are not just compliance tools 4 they are IP defence evidence. Reframe as: "Export occurs only within regulator-authorised named patient pathways. Uncontrolled diversion remains prohibited."

Biologics-Specific Legal Considerations Enhanced Scrutiny Factors Parallel movement of biologics attracts stronger IP scrutiny due to pharmacovigilance requirements, batch traceability demands, and cold chain integrity concerns. Governance Response Your controls address patient-level logs, shipping audits, and medical oversight 4 transforming the narrative from "uncontrolled grey market activity" to "structured compassionate supply ecosystem." This distinction is decisive in injunction hearings, as opposing counsel loses the argument that parallel export equals uncontrolled activity.

The Integrated Legal Narrative

  1. TRIPS Flexibility TRIPS allows international exhaustion choices as sovereign decisions.
  2. Indian Recognition India recognises lawful import/export flexibility post-first sale.
  3. Authorised Supply Product originates from authorised supply chain with documented provenance.
  4. Regulator Approval Export occurs only upon foreign regulator- approved named patient request.
  5. Governance Controls Controls prevent commercialisation or inducement activities.
  6. Legal Conclusion Activity constitutes regulator-authorised patient access, not unlawful parallel trade. Strategic Positioning: You are no longer defending price arbitrage 4 you are defending patient access continuity within international IP flexibilities. Courts evaluate these differently.

Injunction-Resistant Positioning Core Principle Characterise as regulator-authorised, patient- specific medical access rather than commercial parallel trade. Balance of Convenience Programme demonstrates humanitarian purpose, physician initiation, and absence of market substitution. Counter-Arguments TRIPS-consistent exhaustion, lawful first sale, foreign regulator authorisation, and governance controls strengthen resistance. Biologics Safeguards Cold-chain documentation, batch traceability, and pharmacovigilance oversight rebut safety-based injunction arguments.

High-Risk Language to Avoid Never Claim "Patent rights are exhausted globally" "Exports are unrestricted under Indian law" "Named patient programmes override patents" "Export leakage equals global IP exposure" These statements are legally vulnerable and undermine the entire framework. Instead State "Uncontrolled export creates IP exposure. Structured regulator-authorised named patient export represents a permitted pathway within international IP flexibilities." This single shift aligns documentation with real objectives and transforms the narrative from defensive to structurally justified. Strategic Outcome: By framing activity as structured compassionate access supported by international IP flexibilities, the balance of convenience shifts toward continued patient treatment, making interim injunctions more difficult to sustain.